Opportunity Information: Apply for PAR 12 073

  • The National Institutes of Health in the health sector is offering a public funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (SBIR R44)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
  • This funding opportunity was created on Sep 18, 2014 and posted on Jan 11, 2012.
  • Applicants must submit their applications by May 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Each selected applicant is eligible to receive up to $150,000.00 in funding.
  • Eligible applicants include: Small businesses.
Apply for PAR 12 073

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The NINDS Exploratory Clinical Trials for Small Business (SBIR R44) opportunity (Funding Opportunity Number PAR-12-073) is a National Institutes of Health (NIH) grant program designed specifically to help eligible small business concerns move promising neurological products into investigator-initiated exploratory clinical trials. The core intent of the announcement is to give small companies a clear funding path to run early, exploratory human studies that generate the kind of clinical evidence needed to advance development decisions, support later-stage trials, and reduce technical and regulatory uncertainty. The clinical trials supported under this program must align with the mission and priorities of the National Institute of Neurological Disorders and Stroke (NINDS), meaning the work should address diseases, disorders, or injuries of the brain, spinal cord, peripheral nerves, or related neuromuscular systems in a way that fits NINDS program goals.

The FOA is broad in the kinds of interventions and technologies it will consider, as long as they are relevant to NINDS. It allows exploratory clinical trials that evaluate drugs and small molecules, biologics, medical devices, and diagnostics, and it also allows clinical testing of surgical approaches, behavioral interventions, and rehabilitation therapies. In other words, it is not limited to one modality or product category; it is aimed at enabling small businesses to test clinically meaningful innovations across the range of neurological care and research. Because the focus is on exploratory clinical trials, the expectation is generally that projects will be structured to answer early clinical questions such as feasibility, safety signals, dosing/parameter selection, proof-of-concept, biomarker performance, usability, or other data needed to justify and design subsequent pivotal studies.

A key structural restriction of this program is that it supports only SBIR Phase II and Fast Track applications. Standalone Phase I applications are not supported under this announcement, but Phase I can be included if the applicant uses the Fast Track mechanism (which combines Phase I and Phase II in a single coordinated application with defined milestones for transition). This means the program is oriented toward projects that are beyond the earliest concept stage and are ready for, or approaching, clinical evaluation with a credible development plan. The funding instrument type is a grant, the activity category is Health, and the CFDA number listed is 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).

Eligibility is limited to small businesses, consistent with SBIR requirements, and the posting indicates there is no cost sharing or matching requirement, which can be important for small companies trying to preserve capital while generating clinical data. The award ceiling shown in the provided listing is $150,000, though applicants typically need to confirm budget rules and any NIH policy updates by reviewing the full FOA text because SBIR budget guidance can depend on project scope, justification, and NIH-specific limits or waivers.

From an administrative standpoint, the opportunity was originally posted on January 11, 2012, with the record showing an original closing date of January 7, 2015, and a current closing date of May 7, 2015, after which it was archived on June 6, 2015. The administering agency is the National Institutes of Health, with NINDS as the sponsoring institute. Applicants who need the full announcement details were directed to the NIH Grants Guide page for PAR-12-073, and the listing provides NIH Office of Extramural Research (OER) webmaster contact emails for technical access or linking problems.

FAQs: NINDS Exploratory Clinical Trials for Small Business (SBIR R44) - PAR-12-073

What is PAR-12-073 (NINDS Exploratory Clinical Trials for Small Business - SBIR R44)?

PAR-12-073 is an NIH funding opportunity from the National Institute of Neurological Disorders and Stroke (NINDS) intended to help eligible small business concerns advance promising neurological products into investigator-initiated exploratory clinical trials. The emphasis is on early, exploratory human studies that generate clinical evidence to inform development decisions, support later-stage trials, and reduce technical and regulatory uncertainty.

What is the main goal of this program?

The core goal is to provide a clear funding path for small businesses to run exploratory clinical trials in humans for neurological innovations. These trials are expected to produce data that helps determine next development steps, strengthens the design of future studies, and helps address uncertainties that can block progress toward larger trials or later development stages.

Which NIH institute sponsors this opportunity?

The sponsoring institute is NINDS, part of the National Institutes of Health (NIH).

What kinds of conditions or body systems must the project address to fit NINDS priorities?

Projects must align with the NINDS mission and priorities and address diseases, disorders, or injuries of the brain, spinal cord, peripheral nerves, or related neuromuscular systems in a way that fits NINDS program goals.

What types of clinical trials are supported under this FOA?

This opportunity supports investigator-initiated exploratory clinical trials. The intent is generally to answer early clinical questions, such as feasibility, safety signals, dosing or parameter selection, proof-of-concept, biomarker performance, usability, or other kinds of data needed to justify and design later (including pivotal) studies.

What product types or intervention modalities are eligible for clinical testing?

The FOA is broad and can support exploratory clinical trials evaluating drugs and small molecules, biologics, medical devices, and diagnostics. It also allows clinical testing of surgical approaches, behavioral interventions, and rehabilitation therapies, as long as the work is relevant to NINDS.

Is this program limited to one kind of technology (for example, only drugs or only devices)?

No. The program is not limited to a single product category or modality. It is designed to enable small businesses to test clinically meaningful innovations across the spectrum of neurological care and research, provided the project aligns with NINDS priorities.

Which SBIR application types are allowed under PAR-12-073?

This FOA supports only SBIR Phase II and Fast Track applications. Standalone Phase I applications are not supported under this announcement.

Can a Phase I effort be included at all?

Yes, but only through the Fast Track mechanism, which combines Phase I and Phase II in a single coordinated application with defined milestones for transition from Phase I to Phase II.

What does the Phase II and Fast Track limitation imply about project readiness?

It means the program is oriented toward projects that are beyond the earliest concept stage and are ready for, or approaching, clinical evaluation with a credible development plan.

Who is eligible to apply?

Eligibility is limited to small businesses, consistent with SBIR requirements.

Is cost sharing or matching required?

No. The posting indicates there is no cost sharing or matching requirement.

What is the funding instrument and activity category listed for this opportunity?

The funding instrument type is a grant. The activity category is Health.

What CFDA number is associated with this program?

The CFDA number listed is 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).

What award amount is shown in the listing?

The award ceiling shown in the provided listing is $150,000.

Should applicants rely only on the listed award ceiling?

No. The listing notes that applicants typically need to confirm budget rules and any NIH policy updates by reviewing the full FOA text, since SBIR budget guidance can depend on project scope, justification, and NIH-specific limits or waivers.

When was the opportunity originally posted?

The opportunity record shows it was originally posted on January 11, 2012.

What were the closing dates shown for this opportunity?

The record shows an original closing date of January 7, 2015, and a current closing date of May 7, 2015.

Is this funding opportunity still active?

No. The listing indicates it was archived on June 6, 2015.

Where were applicants directed to find the full announcement details?

Applicants were directed to the NIH Grants Guide page for PAR-12-073 for the full announcement details.

Who administers this opportunity?

The administering agency is the National Institutes of Health (NIH), with NINDS as the sponsoring institute.

Who should be contacted for technical access or linking problems related to the announcement?

The listing provides NIH Office of Extramural Research (OER) webmaster contact emails for technical access or linking problems.

What kind of evidence is this program trying to help small businesses generate?

The program is designed to support collection of exploratory clinical evidence in humans that can reduce technical and regulatory uncertainty and guide decisions about whether and how to proceed to later-stage development and trials.

Does this FOA support trials that focus on feasibility and usability questions rather than definitive clinical outcomes?

Yes. Because it is aimed at exploratory clinical trials, the expectation is that projects may focus on early questions such as feasibility, safety signals, parameter or dosing selection, proof-of-concept, biomarker performance, and usability, among other data needed to plan subsequent studies.

Browse more: Small Business Grants, Small Business Loans

Browse more business programs for Business Consultants

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Wisconsin DNR Wildlife Intern Sponsorship

Previous opportunity: NINDS Exploratory Clinical Trials for Small Business (STTR R42)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 12 073

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 12 073) also looked into and applied for these:

Funding Opportunity
NINDS Competing Renewal Awards of STTR Phase II Grants (Phase IIB) for Exploratory Clinical Trials (STTR R42) Apply for PAR 12 074

Funding Number: PAR 12 074
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NINDS Competing Renewal Awards of SBIR Phase II Grants (Phase IIB) for Exploratory Clinical Trials (SBIR R44) Apply for PAR 12 075

Funding Number: PAR 12 075
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NINDS Competing Renewal Awards of SBIR Phase II (Phase IIB) Grants (SBIR R44) Apply for PAR 12 077

Funding Number: PAR 12 077
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NINDS Competing Renewal Awards of STTR Phase II (Phase IIB) Grants (STTR R42) Apply for PAR 12 076

Funding Number: PAR 12 076
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
CHILDRENS HEALTH INSURANCE PROGRAM REAUTHORIZATION ACT (CHIPRA)PROSPECTIVE PAYMENT SYSTEM (PPS) FOR FEDERALLY QUALIFIED HEALTH CENTERS (FQHCs) AND RURAL HEALTH CLINICS (RHCs) TRANSITION GRANTS SECOND RELEASE Apply for CMS 1Z0 12 001

Funding Number: CMS 1Z0 12 001
Agency: Centers for Medicare Medicaid Services
Category: Health
Funding Amount: $500,000
Molecular Characterization of Salivary Gland Tumors (R21) Apply for RFA DE 12 012

Funding Number: RFA DE 12 012
Agency: National Institutes of Health
Category: Health
Funding Amount: $200,000
Molecular Characterization of Salivary Gland Tumors (R01) Apply for RFA DE 12 011

Funding Number: RFA DE 12 011
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Conducting Research on Moderate Acute Malnutrition in Humanitarian Emergencies Apply for RFA GH 12 006

Funding Number: RFA GH 12 006
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: $2,000,000
Service Area Competition Additional Area (SAC AA) (Anchorage, AK) Apply for HRSA 12 169

Funding Number: HRSA 12 169
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Dental Reimbursement Program Apply for HRSA 12 080

Funding Number: HRSA 12 080
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Biodemography of Aging (R21) Apply for PAR 12 079

Funding Number: PAR 12 079
Agency: National Institutes of Health
Category: Health
Funding Amount: $200,000
Biodemography of Aging (R01) Apply for PAR 12 078

Funding Number: PAR 12 078
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Biodemography of Aging (R03) Apply for PAR 12 080

Funding Number: PAR 12 080
Agency: National Institutes of Health
Category: Health
Funding Amount: $100,000
Leadership Group for a Clinical Research Network on Antibacterial Resistance (UM1) Apply for RFA AI 12 019

Funding Number: RFA AI 12 019
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
NINDS Institutional Center Core Grants to Support Neuroscience Research (P30) Apply for PAR 12 081

Funding Number: PAR 12 081
Agency: National Institutes of Health
Category: Health
Funding Amount: Case Dependent
Affordable Care Act Maternal, Infant, and Early Childhood Home Visiting Research Program Apply for HRSA 12 159

Funding Number: HRSA 12 159
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Newborn Screening Technical Assistance and Data Repository Program Apply for HRSA 12 070

Funding Number: HRSA 12 070
Agency: Health Resources and Services Administration
Category: Health
Funding Amount: Case Dependent
Health Strategic Information (SI) Apply for APS656 12 000004

Funding Number: APS656 12 000004
Agency: Mozambique USAID Maputo
Category: Health
Funding Amount: $300,000
Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO 11 110202CONT12

Funding Number: CDC RFA SO 11 110202CONT12
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent
Surveillance Program Announcement Behavioral Risk Factor Surveillance System, Apply for CDC RFA SO 11 110102CONT12

Funding Number: CDC RFA SO 11 110102CONT12
Agency: Centers for Disease Control and Prevention
Category: Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 073", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.